US FDA nod for 1st pill to replace jabs to fight high cholesterol

The US Food and Drug Administration has approved the first oral PCSK9 inhibitor, known as Lipfendra, for the treatment of high cholesterol. This drug provides a daily tablet alternative for adults who struggle to manage their LDL cholesterol levels, including those with heterozygous familial hypercholesterolaemia.

Clinical trials included over 3,000 adults. The data showed that patients using this medication in addition to statins experienced LDL cholesterol reductions of 56 to 59 percent over a 24-week period. These results match the efficacy of existing injectable PCSK9 inhibitors, providing a non-invasive option for patients who require significant cholesterol reduction.

While the FDA approval is a major step, the medication is not currently available for the Indian market. Marketing the drug in India requires separate approval from the Central Drugs Standard Control Organisation. Experts note that this regulatory path may involve additional clinical trials to meet domestic standards.

Cardiologists view this as a positive development for patient care. It offers a solution for high-risk patients who find standard oral medications insufficient but wish to avoid the inconvenience of injections. Despite the potential, medical professionals do not expect this drug to replace existing first-line treatments immediately.